Deferiprone
Deferiprone is an iron chelator (a medicine that binds iron) used to treat iron overload from repeated blood transfusions in people with thalassemia syndromes, and, for Ferriprox products, sickle cell disease or other anemias.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 7 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Deferiprone (Ferriprox) is an iron chelator that grabs extra iron so the body can flush it out in the urine, used for iron overload from repeated transfusions in thalassemia syndromes and, with Ferriprox products, sickle cell disease or other anemias; a specialist medicine, it has been on the U.S. market since about 2015 and is available generically. Stomach upset (nausea, vomiting, belly pain) and joint pain are what people notice most. The boxed warning is agranulocytosis, a dangerous drop in infection-fighting white blood cells, so expect regular blood counts and treat any fever, chills or sore throat as a reason to stop it and call your doctor right away.
Clinical pearls
- Leave at least four hours between deferiprone tablets and antacids or supplements containing iron, aluminum or zinc.
- Avoid diclofenac, probenecid and milk thistle (silymarin), which can slow how your body breaks down deferiprone.
- Make sure your tablet matches your schedule, since one Ferriprox tablet is taken twice daily and the others three times daily.
- Both partners need effective contraception during treatment and afterward, at least six months for women and three months for men.
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾
Deferiprone can cause agranulocytosis, a dangerous drop in white blood cells that can lead to serious infections and death. A milder drop (neutropenia) can come first.
Your neutrophil count (ANC) must be checked before you start and regularly during treatment. If neutropenia or an infection develops, treatment is interrupted. Report any sign of infection right away, such as fever, chills or sore throat.
Patient information guide A plain-language walkthrough of Deferiprone, written from its FDA label.
What Deferiprone is used for
▾
Deferiprone is used for transfusional iron overload. Approvals differ by product.
- Ferriprox Oral Solution: adults and children 3 years and older with thalassemia syndromes, sickle cell disease or other anemias.
- Ferriprox Tablets: adults and children 8 years and older with thalassemia syndromes, sickle cell disease or other anemias.
- Deferiprone tablets (generic): adults with thalassemia syndromes when current chelation therapy is inadequate.
- Not established for myelodysplastic syndrome or Diamond Blackfan anemia.
How Deferiprone works
▾
Deferiprone is a chelating agent that has an affinity for ferric ions (iron III). It binds iron to form stable complexes, which the body can then clear.
The main breakdown product no longer binds iron and leaves mostly in the urine.
Deferiprone dosage
▾
Deferiprone is taken by mouth, with the dose based on your body weight. Ferriprox Oral Solution is taken three times a day. Ferriprox Tablets come in a twice-daily and a three-times-daily version. Generic deferiprone tablets are taken three times a day.
- Check that your tablet type matches your dosing schedule.
- If swallowing tablets is hard, ask about the oral solution.
- Food did not change how the body handled Ferriprox tablets in studies.
- Your doctor may start with a lower dose and increase gradually to ease stomach upset.
Follow your prescriber and the label for the exact dose and for what to do about a missed dose.
Dosing details from the FDA-approved label
From the Deferiprone prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Transfusional iron overload due to thalassemia syndromes, sickle cell disease or other anemias (adult and pediatric patients) - FERRIPROX Tablets (twice a day), 1,000 mg
- Starting oral dosage 75 mg/kg/day (actual body weight) in two divided doses per day (taken approximately 12 hours apart), with food
- Round the total daily dose to the nearest 500 mg (half-tablet)
- To minimize gastrointestinal upset when first starting therapy, dosing can start at 45 mg/kg/day and increase weekly by 15 mg/kg/day increments until the full pres
- Maximum: 99 mg/kg/day (actual body weight) in two divided doses taken approximately 12 hours apart with food
- Tailor dosage adjustments to the individual patient's response and therapeutic goals (maintenance or reduction of body iron burden).
- Transfusional iron overload due to thalassemia syndromes, sickle cell disease or other anemias (adult and pediatric patients) - FERRIPROX Tablets (three times a day), 1,000 mg
- Starting oral dosage 75 mg/kg/day (actual body weight) in three divided doses per day
- Round dose to the nearest 500 mg (half-tablet)
- To minimize gastrointestinal upset when first starting therapy, dosing can start at 45 mg/kg/day and increase weekly by 15 mg/kg/day increments until the full prescribed dose is achieved
- Maximum: 99 mg/kg/day (actual body weight) in three divided doses per day
- Tailor dosage adjustments to the individual patient's response and therapeutic goals (maintenance or reduction of body iron burden).
- Transfusional iron overload due to thalassemia syndromes, sickle cell disease or other anemias (adult and pediatric patients) - FERRIPROX Oral Solution
- Starting oral dosage 25 mg/kg (actual body weight), three times per day for a total of 75 mg/kg/day
- Round dose to the nearest 2.5 mL. Dosing can start at 45 mg/kg/day and increase weekly by 15 mg/kg/day increments until the full prescribed dose is achieved
- Maximum: 33 mg/kg (actual body weight), three times per day for a total of 99 mg/kg/day
- Tailor dosage adjustments to the individual patient's response and therapeutic goals (maintenance or reduction of body iron burden).
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION Deferiprone tablets are available in two formulations. A 1,000 mg formulation and a 500 mg formulation, which have different dosing regimens to achieve the same total daily dosage. ( 2.1 ) To prevent medication errors, before prescribing and dispensing, ensure that the tablet formulation is appropriate for the dosing regimen. Each tablet has distinct identifying characteristics. ( 2.1 , 3 ) Deferiprone tablets (three times a day), 1,000 mg: Starting oral dosage: 75 mg/kg/day (actual body weight) in three divided doses ( 2.3 ) Maximum oral dosage: 99 mg/kg/day (actual body weight) in three divided doses ( 2.3 ) Deferiprone tablets (three times a day), 500 mg: Starting oral dosage: 75 mg/kg/day (actual body weight) in three divided doses ( 2.4 ) Maximum oral dosage: 99 mg/kg/day (actual body weight) in three divided doses ( 2.4 ) 2.1 Important Dosage and Administration Information Deferiprone tablets are available in a 1,000 mg formulation and a 500 mg formulation, which have different oral dosing regimens to achieve the same total daily dosage. Deferiprone tablets (three times a day) - 1,000 mg - given three times a day [see Dosage and Administration (2.3) ] Deferiprone tablets - 500 mg - given three times a day [see Dosage and Administration (2.4) ] To prevent medication errors, before prescribing and dispensing, ensure that the tablet formulation is appropriate for the dosing regimen. Each tablet has distinct identifying characteristics [see Dosage Forms and Strengths (3) ]. For patients who have trouble swallowing tablets, consider the use of oral solution (see the prescribing information for oral solution). Monitoring for Safety Due to the risk of agranulocytosis, monitor ANC before and during deferiprone therapy. Test ANC prior to start of deferiprone therapy and monitor on the following schedule during treatment: First six months of therapy: Monitor ANC weekly; Next six months of therapy: Monitor ANC once every two weeks; After one year of therapy: Monitor ANC every two to four weeks (or at the patient's blood transfusion interval in patients that have not experienced an interruption due to any decrease in ANC [see Warnings and Precautions (5.1) ] . Due to the risk of hepatic transaminase elevations, monitor ALT before and monthly during deferiprone therapy [see Warnings and Precautions (5.2) ] .
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Deferiprone side effects
▾
The most common side effects in clinical trials were:
Common side effects
- Nausea
- Vomiting
- Stomach pain or discomfort
- Joint pain (arthralgia)
- Increased liver enzyme (ALT) levels
- Low neutrophil count (neutropenia)
- Diarrhea
- Increased appetite
- In sickle cell disease or other anemias: fever, headache, bone pain, back pain, cough and sore throat
When to get medical help
- Fever, sore throat, chills or any sign of infection: stop the medicine and call your doctor right away, as this can signal agranulocytosis.
- A low neutrophil count found on a blood test: your doctor will interrupt treatment.
- Persistent rise in liver enzymes: your doctor may pause the medicine.
- Low zinc levels: your doctor may recommend a supplement.
- Allergic reactions such as hives, swelling around the eyes with rash, or Henoch-Schönlein purpura: get medical help.
- Pregnancy while taking this medicine: tell your doctor right away.
Act quickly on any signs of infection, as well as allergic reactions, or lab results showing low neutrophils, high liver enzymes or low zinc.
Deferiprone warnings and precautions
▾
Agranulocytosis and neutropenia are the biggest risks. They can be fatal. Your ANC is checked weekly for the first six months, then every two weeks for the next six months, then every two to four weeks.
- Liver enzymes (ALT) are checked monthly.
- Zinc levels are monitored and low levels are supplemented.
- It can cause fetal harm.
- Stop and report any infection symptoms immediately.
Deferiprone interactions
▾
Some medicines and supplements can change how deferiprone works or raise its risks.
- Drugs that lower neutrophils: add to the risk of agranulocytosis.
- UGT1A6 inhibitors (diclofenac, probenecid, silymarin/milk thistle): can slow deferiprone breakdown.
- Iron, aluminum or zinc products, including antacids: deferiprone binds them, so wait at least 4 hours.
- Alcohol: increased release of drug from a Ferriprox twice-a-day tablet in lab testing.
Interactions listed in the FDA-approved label
From the Deferiprone prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Drugs associated with neutropenia or agranulocytosis: Other drugs known to be associated with neutropenia or agranulocytosis should not be given together with deferiprone tablets. Avoid co-administration. If co-administration is unavoidable, closely monitor the absolute neutrophil count.
- UGT1A6 inhibitors (e.g., diclofenac, probenecid, or silymarin (milk thistle)): UGT1A6 inhibitors are listed as drugs that affect deferiprone tablets through UDP-glucuronosyltransferases. Avoid use of UGT1A6 inhibitors with deferiprone tablets.
- Polyvalent cations (e.g., iron, aluminum, and zinc) and other medications (e.g., antacids) or supplements containing them: Deferiprone has the potential to bind polyvalent cations. Allow at least a 4-hour interval between deferiprone tablets and these medications or supplements.
Read the label’s full interactions text
7 DRUG INTERACTIONS • Drugs Associated with Neutropenia or Agranulocytosis: Avoid co-administration. If co-administration is unavoidable, closely monitor the absolute neutrophil count. ( 7.1 ) • UGT1A6 Inhibitors: Avoid co-administration. ( 7.2 ) • Polyvalent Cations: Allow at least a 4-hour interval between administration of deferiprone tablets and drugs or supplements containing polyvalent cations (e.g., iron, aluminum, or zinc). ( 2.2 , 7.2 ) 7.1 Drugs Associated with Neutropenia or Agranulocytosis Avoid co-administration of deferiprone tablets with other drugs known to be associated with neutropenia or agranulocytosis. If co-administration is unavoidable, closely monitor the absolute neutrophil count [see Warnings and Precautions ( 5.1 )] . 7.2 Effect of Other Drugs on Deferiprone Tablets UDP-Glucuronosyltransferases (UGTs): Avoid use of UGT1A6 inhibitors (e.g., diclofenac, probenecid, or silymarin (milk thistle)) with deferiprone tablets [see Dosage and Administration ( 2.2 ), Adverse Reactions ( 6.1 ), Clinical Pharmacology ( 12.3 )] . Polyvalent Cations: Deferiprone has the potential to bind polyvalent cations (e.g., iron, aluminum, and zinc); allow at least a 4-hour interval between deferiprone tablets and other medications (e.g., antacids), or supplements containing these polyvalent cations [see Dosage and Administration ( 2.2 )] .
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Deferiprone
▾
- Do not use if allergic to deferiprone or its ingredients.
- Tell your doctor if you have had low white blood cell counts.
- Pregnancy testing is recommended before starting for females who could become pregnant.
- Use effective contraception: females during treatment and 6 months after, males 3 months after.
- Breastfeeding is not recommended during treatment and for 2 weeks after.
- Children: age limits depend on the product.
Deferiprone overdose
▾
No cases of acute overdose have been reported, and there is no specific antidote. In children given 2.5 to 3 times the recommended dose for over a year, nerve and movement problems occurred, such as unsteadiness, double vision and slowed movement. These gradually went away after stopping the medicine.
What Deferiprone does in the body
▾
Deferiprone binds iron. No clinical studies assessed how the dose relates to the amount of iron removed. At the maximum approved dose, it does not prolong the QT interval (a heart rhythm measure) to any clinically relevant extent.
How your body processes Deferiprone
▾
Deferiprone appears in the blood within minutes and peaks in about 1 to 2 hours. Its half-life is roughly 2 hours. The liver enzyme UGT1A6 breaks it down mainly into a metabolite that does not bind iron. About 75% to 90% of a dose is found in urine within 24 hours.
How to store Deferiprone
▾
Store at 20°C to 25°C (68°F to 77°F) ; . Store at 20° to 25°C (68° to 77°F) .
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Deferiprone
17 supplements and herbal products have documented interactions with Deferiprone in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 1
- Moderate · 7
- Minor · 9
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Deferiprone: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Deferiprone — the kind of thing our pharmacy team would talk through with you at the counter.
What is deferiprone for?
▾
Why do I need so many blood tests?
▾
What symptoms should I call about right away?
▾
Will it upset my stomach?
▾
Can I take it with antacids or supplements?
▾
Is it safe in pregnancy?
▾
Is Deferiprone available over the counter?
▾
When was Deferiprone first available?
▾
Who makes Deferiprone?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Deferiprone on HelloPharmacist
Deferiprone forms and strengths (how it comes)
Deferiprone is available in 2 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Deferiprone inactive ingredients by manufacturer.
Tablet
How this form is used
- Ferriprox Tablets treat transfusional iron overload in adults and children 8 years and older with thalassemia syndromes, sickle cell disease or other anemias.
- Deferiprone tablets treat transfusional iron overload in adults with thalassemia syndromes when current chelation therapy is inadequate.
- Ferriprox Tablets come in two 1,000 mg versions with different schedules (twice a day or three times a day), so make sure your tablet matches your schedule.
- Deferiprone tablets come in 1,000 mg and 500 mg versions, each taken three times a day.
- Deferiprone tablets should be separated by at least 4 hours from antacids or supplements containing iron, aluminum or zinc.
Oral solution
How this form is used
- Ferriprox Oral Solution treats transfusional iron overload in adults and children 3 years and older with thalassemia syndromes, sickle cell disease or other anemias.
- Ferriprox Oral Solution is taken by mouth three times per day.
- Ferriprox Oral Solution is measured by volume based on body weight, so follow your prescriber's directions.
- Ferriprox Oral Solution therapy requires regular ANC, ALT and zinc monitoring.
Deferiprone on the U.S. market: products, makers and brands
How Deferiprone appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
5 companies list 10 Deferiprone product records with the FDA, mostly as tablet, oral solution; the earliest marketing or approval year on record is 2011. Brand names on the directory include Ferriprox; the rest are generics.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (5) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Deferiprone is used (Medicaid data)
A general measure of how commonly Deferiprone is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Deferiprone is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Deferiprone prescribed? Of the 1,601 medications we measure, Deferiprone ranks #1,153 by Medicaid prescriptions — more than 28% of them.
Utilization by Deferiprone product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
Twice-Daily deferiprone 1000 MG Oral Tablet Most dispensed
Summed across the 2 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2685014
deferiprone 100 MG/ML Oral Solution
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1716264
deferiprone 1000 MG Oral Tablet
Summed across the 2 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2180997
deferiprone 500 MG Oral Tablet
Summed across the 1 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 389242
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Deferiprone, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 6 of 17 listed Deferiprone NDCs with Medicaid activity.
Compare Deferiprone products
A representative set of FDA-listed product records for Deferiprone — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Oral solution | ||||
| 100 mg/mL | Oral | Chiesi USA, Inc. | NDA | View NDC → |
| 💊Tablet | ||||
| 500 mg | Oral | AvKARE | ANDA | View NDC → |
| 1000 mg | Oral | Chiesi USA, Inc. × 2 listings | NDA | View NDC → |
| 500 mg | Oral | Dr. Reddy's Laboratories, Inc. | ANDA | View NDC → |
| 1000 mg | Oral | Dr. Reddy's Laboratories, Inc. | ANDA | View NDC → |
| 500 mg | Oral | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 1000 mg | Oral | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 500 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 1000 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
Showing 10 of 10 products — FDA National Drug Code Directory. See every product, package size and price: browse all 10 Deferiprone NDCs →
Deferiprone side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Deferiprone — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Deferiprone in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Deferiprone FDA approval history
How Deferiprone went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Deferiprone recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Deferiprone recalls since July 2021.
✅No Deferiprone recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 11645 2 dose forms · 4 strengths
-
Dose form (SCDF) Oral Solution RxCUI 1716263In current FDA listingsClinical drug / strength (SCD) 100 MG/MLRxCUI 1716264 -
Dose form (SCDF) Oral Tablet RxCUI 393424In current FDA listingsClinical drug / strength (SCD) Twice-Daily deferiprone 1000 MGRxCUI 2685014500 MGRxCUI 3892421000 MGRxCUI 2180997
Look up RxCUI 11645 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Deferiprone supply and shortage status
Whether Deferiprone is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Deferiprone brand names
Deferiprone is sold under one brand name in the FDA directory — Ferriprox. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Deferiprone: manufacturers and labelers
5 companies list Deferiprone products with the FDA. By number of product records, the largest are Chiesi USA, Inc., Dr. Reddy's Laboratories, Inc., Hikma Pharmaceuticals USA Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Deferiprone drug class (RxNorm)
Deferiprone belongs to the Iron Chelator class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Deferiprone page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Chiesi USA, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →